ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug
Phase 3negativeZynlontarituximabNegative
AI Analysis
Summary
ADC Therapeutics' Zynlonta plus rituximab failed its confirmatory Phase 3 trial for diffuse large B cell lymphoma, with 27 deaths reported and no overall survival benefit demonstrated. The negative results cast significant doubt on the drug's viability as a second-line treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
27 deaths in confirmatory trial; no overall survival benefit demonstrated
Importance:9/10
Sentiment:
-0.95
Phase 3 failurelymphomasafety concernsoverall survivalconfirmatory trial
Related Companies
Read the original article
Published by BioSpace on June 4, 2026 1:08 PM